Scynex­is will pit a new class of an­ti­fun­gals against yeast in­fec­tions — and it won't come cheap

The FDA ush­ered in a new class of triter­penoid an­ti­fun­gals this week, giv­ing Scynex­is the OK for its oral ibrex­a­fungerp — a non-azole treat­ment the com­pa­ny de­signed to de­throne Pfiz­er’s flu­cona­zole in vagi­nal yeast in­fec­tion.

The de­ci­sion came right on time for Scynex­is’ June 1 PDU­FA date, and was based on two Phase III tri­als in which about 50% and 63% of pa­tients giv­en the drug, re­spec­tive­ly, saw all signs and symp­toms of their yeast in­fec­tions dis­ap­pear by day 10.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER